Matthew S. Zabriskie

Department of Radiology and Imaging Sciences, University of Utah

Affiliated withUniversity of Utah

Research Area

Biography

Matthew S. Zabriskie has not added Biography.
If you are Matthew S. Zabriskie and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 1	2023

Other Publications

Article	Year
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood\| PubMed ID: 21908430	2011
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer cell\| PubMed ID: 22169110	2011
Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nature reviews. Cancer\| PubMed ID: 22825216	2012
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood\| PubMed ID: 23223358	2013
Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis. Cancer research\| PubMed ID: 23576564	2013
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer cell\| PubMed ID: 25132497	2014
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia\| PubMed ID: 25134459	2015
shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. Blood\| PubMed ID: 25573989	2015
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1. Leukemia\| PubMed ID: 25676420	2015
A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia. Leukemia\| PubMed ID: 25721898	2015
Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm. Experimental hematology\| PubMed ID: 25912019	2015
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 26673800	2016
Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib. Leukemia\| PubMed ID: 28819281	2017
A novel fusion in pediatric T-cell acute lymphoblastic leukemia. Haematologica\| PubMed ID: 29284681	2018
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Cancer cell\| PubMed ID: 31543464	2019
Apolipoprotein E knockout rabbit model of intracranial atherosclerotic disease. Animal models and experimental medicine\| PubMed ID: 32613180	2020
Rabbit models of intracranial atherosclerotic disease for pathological validation of vessel wall MRI. The neuroradiology journal\| PubMed ID: 33325806	2021
SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA. Blood cancer discovery\| PubMed ID: 34027418	2021
MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis. Blood\| PubMed ID: 34780648	2022